Occupational and Chemical Exposure that may cause MPNs, Along with Familial Clustering

dangerous occupations may cause MPNs

Some Jobs and Familial Clustering are Likely Suspects in Possibly developing an MPN by David Wallace The daily exposure to toxic chemicals over the span of a career may be a strong factor in leading numerous workers to develop an MPN.  Certain chemicals we know are problematic, include Benzene and Toluene, as well as radiation.  […]

The Health Benefits of Dog Ownership for MPN Cancer Patients

A Pet is like Medication Minus the Side Effects Second in a Series – “Natural Healing Ideas for MPN patients” by David Wallace There have been many studies weighing the emotional and physical benefits of owning a pet.  One study found that people with pets had significantly lower heart rates and blood pressure than non […]

HemaSphere is an OPEN ACCESS Journal dedicated to support hematology patient care research and education worldwide

MPN hematology journal

European Hematology Association publishes new journal with Wolters Kluwer June 22, 2017, Madrid – The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid. HemaSphere is an open access journal dedicated to support hematology patient care, research […]

Incyte conducts Phase 2 Clinical Trials for Myelofibrosis and Essential Thrombocythemia

Incyte clinical trials

Myelofibrosis A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis Talk to your doctor if you are interested in participating […]

The Health Benefits of Therapeutic Oncology Massage for MPN Cancer patients

therapeutic massage for MPN cancer patient

First in a Series – “Natural Healing Ideas for MPN patients” by David Wallace A Personal Perspective  Over the years, I have enjoyed a good massage on rare occasion.  An intense week of maneuvering the challenging slopes in Alta, Deer Valley and Snowbird, Utah comes to mind, about 15 years ago (pre-PV).  After 3 or […]

David Wallace, PV Reporter honored with 2016 Cure Magazine MPN Hero Award

David Wallace PV Reporter 2016 MPN Hero award winner

Our Third Year attending the MPN Heroes Program by David Wallace For the past 4 years, Cure Magazine and Incyte Corporation have recognized leaders within the MPN community with the MPN Hero award.  The two categories include commitment to the individual or community.  I am honored to receive this award for “commitment to the broader […]

PV Reporter Covers ASH 2016

A Year of Consolidating MPN Research by David Wallace In December 2016, I attended the colossal, premiere hematology event in the world (ASH – American Society of Hematology), in San Diego with a hopeful eye for the 3rd straight year.  But there were no ground breaking gene discoveries like 2014, when the Calreticulin (CALR) mutation […]

Kickboxing my way to Sunshine!

exercise helps ET

by Christine Kennedy Happy new year.  I hope everyone will be in their best place this year.  This disease has a depression end and numbers have a deep hold on us.  Last year, physically and mentally, was my best year. Exercise Beats Exhaustion I started kickboxing.  I think my body needed exercise. Giving in to […]

Dr Kiladjian at ASH 2016 Reviews Outcomes of MPN Patients after Interferon therapy discontinuation

Dr Kiladjian ASH 2016 interview PV Reporter

Early Treatment with Interferon provides better Patient Outcomes Second in ASH 2016 Series by David Wallace Dr. Jean–Jacques Kiladjian, MD, PhD is the head of the Clinical Investigation Center at Saint–Louis Hospital and a professor at Paris Diderot University in Paris, France.  Dr Kiladjian and David Wallace discuss the outcomes of a retrospective study of […]

ASH 2016 Dr Rampal shares MPN updates on Clinical Research with PV Reporter

Ruxolitinib (Jakafi) plus PIM and CDK4/6 Inhibitors First in ASH 2016 Series by David Wallace Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center in New York City, presented pre-clinical data from a trial of a three drug combination in animal models in MPNs.  The combination of ruxolitinib, PIM447 ( a drug that targets PIM […]

Check out more resources at MPN Cancer Connection!Click here
error: Content is protected !!